Motif Bio PLC Motif selected to present at Biotech Showcase

TIDMMTFB

Motif Bio PLC

07 December 2015

Motif Bio plc

("Motif" or the "Company")

Motif selected to present at Biotech Showcase, San Francisco, January 2016

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has been selected to present at the Biotech Showcase 2016, San Francisco, on:

Monday, January 11, 2016 at 1400 PST

Track: D - Powell (3rd Floor)

Biotech Showcase, which runs alongside the largest healthcare investor event of the year - the JP Morgan Annual Healthcare Conference - is an investor and partnering conference dedicated to providing private and public life sciences companies an opportunity to meet with investors and pharmaceutical executives from around the world.

Graham Lumsden, Chief Executive Officer at Motif, said: "Being selected to present at such an important event is recognition of Motif's success to date and future potential. Members of the Motif Leadership Team will be in San Francisco to meet pharma and biotech investors and partners attending the Biotech Showcase and JP Morgan conference."

For further information please contact

Enquiries

 
 Motif Bio plc                           info@motifbio.com 
  Graham Lumsden (Chief Executive 
  Officer) 
  David Huang (Chief Medical Officer) 
  www.motifbio.com 
 Zeus Capital Limited (NOMINATED 
  ADVISER and BROKER) 
  Phil Walker/Dan Bate                   +44 (0) 20 
  Dominic Wilson                          3829 5000 
 Northland Capital Partners Limited 
  (BROKER) 
  Patrick Claridge/ David Hignell        +44 (0) 20 
  John Howes/ Mark Treharne (Broking)     7382 1100 
 
                                           +49 (0) 89 
 MC Services AG (TRADE PR)                 210 2280 
  Raimund Gabriel                          +44 (0) 207 
  Shaun Brown                              148 5998 
 Plumtree Capital Limited (FINANCIAL 
  ADVISER)                               +44 (0) 207 
  Stephen Austin                          183 2493 
 Yellow Jersey PR Limited (FINANCIAL 
  PR) 
  Charles Goodwin                        +44 (0) 7747 
  Dominic Barretto                        788 221

Notes to Editors:

Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria. For additional information about Motif please visit www.motifbio.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAUGGGWPUPAUBA

(END) Dow Jones Newswires

December 07, 2015 02:00 ET (07:00 GMT)

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024